Latest Japan Startup Funding Rounds
Startup funding in Japan: recent rounds, the companies behind them and their participating investors.
- Rounds
- 399 All time
- Disclosed funding
- $3B 141 disclosed amounts
- Median round
- $2.4M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| SB Surv BioPharma develops oncolytic virus therapies for cancer. | ¥670M | Series B second closeSeries B | Biotech | Japan | Investors | |
| SB Surv BioPharma develops oncolytic virus therapies for cancer. | ≤¥2.7B | AMED ecosystem programme supportUndisclosed | Biotech | Japan | Investors | |
NahatoCompany profile Nahato is a Japanese marketing company providing influencer advertising, social media campaigns and business development services. Nahato is a Japanese marketing company providing influencer advertising, social media campaigns and business development services. | ¥6B | Debt financingUndisclosed | Business services | Japan | Investors | |
| SA Sakana AICompany profile Sakana AI is a Tokyo research company developing nature-inspired AI models and methods. Sakana AI is a Tokyo research company developing nature-inspired AI models and methods. | ~¥32B | Series B cumulative, updated 9 April 2026Series B | AI | Japan | Investors | |
| TI Third IntelligenceCompany profile Researches and develops AI models and products that adapt to individual and organizational needs. Researches and develops AI models and products that adapt to individual and organizational needs. | ¥8B | First funding roundUndisclosed | AI | Japan | Investors | |
OptQC Corp.Company profile OptQC builds optical quantum-computing hardware for research institutions and technology companies. OptQC builds optical quantum-computing hardware for research institutions and technology companies. | ¥1.5B | Series A1Series A | Hardware | Japan | Investors | |
| SB Surv BioPharma develops oncolytic virus therapies for cancer. | ¥1.5B | Series B first closeSeries B | Biotech | Japan | Investors | |
| F FELIQS develops small-molecule medicines for retinal diseases. | $10M | Series A total including extensionSeries A | Biotech | Japan | Investors | |
| XI XPERISUS, Inc.Company profile A travel company developing premium Japanese cultural experiences and distributing them through luxury travel partners. A travel company developing premium Japanese cultural experiences and distributing them through luxury travel partners. | ¥350M | Series A trancheSeries A | Travel tech | Japan | Investors | |
LABTECHSCompany profile LABTECHS develops rapid sterility testing kits and reagents from research at the University of Toyama. LABTECHS develops rapid sterility testing kits and reagents from research at the University of Toyama. | Undisclosed | Go-Tech research grant selectionUndisclosed | Biotech | Japan | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Japan Finance Corporation
NearMe, BALLAS, IRBANK
20rounds0led - 2The Senshu Ikeda Bank, Ltd.
AOI Biosciences, Inc., RadioNano Therapeutics, IntraPhoton
16rounds0led - 3JAFCO Group Co., Ltd.
newmo, indent, QueryLift, Inc.
13rounds2led - 4Mitsubishi UFJ Capital Co., Ltd.
PulmoGate, BionicM, Flyle
9rounds1led - 5Mizuho Capital Co., Ltd.
STRACT, Pay2o, Flyle
8rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.